[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# Neumora Therapeutics, Inc. Common Stock (NMRA)

Neumora Therapeutics' P3 Depressive Disorder Major results for Navacaprant are expected in 1Q26, while recent analyst upgrades suggest a $X price target. However, the stock faces headwinds from negative analyst ratings and concerns over M4 specificity.

### About Neumora Therapeutics, Inc. Common Stock
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases.  
Neumora Therapeutics, Inc. Common Stock uses the ticker $NMRA for trading. Listed in the [Stocks](/list/stocks) category.

### Insights
- Neumora Therapeutics, Inc. Common Stock (NMRA) sentiment near a 52-week low at X.
- Neumora Therapeutics, Inc. Common Stock (NMRA) social dominance is up XXXXXX% from the previous week.
- Neumora Therapeutics, Inc. Common Stock (NMRA) Galaxy Score™ is up XXXXX% from the previous week.

### Price: $XXXX
![Price Line Chart](https://lunarcrush.com/gi/w:600/t:$nmra/c:line/m:close/iv:1d.svg)  
[Price 24-Hour Time-Series Raw Data](/topic/$nmra/time-series/close.tsv)  
The stock price is declining due to negative analyst ratings and market downturn, despite some positive mentions of potential price increases and recent insider buying. The recent surge in social media activity, particularly around options volume and insider transactions, may indicate a short-term speculative interest that is not yet translating into sustained price recovery.  

24-Hour: -XXXX%
7-Day: -XXXX%
30-Day: -XX%

1-Year High: $XXXXX on 2024-12-26  
1-Year Low: $XXXXX on 2025-05-14  
  
  
### AltRank: XXXXX
![AltRank Line Chart](https://lunarcrush.com/gi/w:600/t:$nmra/c:line/m:alt_rank/iv:1d.svg)  
[AltRank 24-Hour Time-Series Raw Data](/topic/$nmra/time-series/alt_rank.tsv)  
Neumora Therapeutics, Inc. Common Stock (NMRA) is currently AltRank #1,528 based on combined combined social and market metrics
Daily Average: XXXXX  
X Week: XXXXX +746  
X Month: XXXXX +455  
X Months: XXXXX -XXX  
X Year: XXXXX +814  
1-Year High: XXXXX on 2025-09-25  
1-Year Low: XX on 2025-02-23  
  
  
### Galaxy Score: XX
![Galaxy Score Line Chart](https://lunarcrush.com/gi/w:600/t:$nmra/c:line/m:galaxy_score/iv:1d.svg)  
[Galaxy Score 24-Hour Time-Series Raw Data](/topic/$nmra/time-series/galaxy_score.tsv)  
Current Value: XX  
Daily Average: XX  
X Week: XX +10  
X Month: XX -XX  
X Months: XX +7  
X Year: XX -X  
1-Year High: XX on 2025-07-09  
1-Year Low: X on 2025-04-04  
  
  
### Engagements: XXX (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$nmra/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$nmra/time-series/interactions.tsv)  
Current Value: XXX  
Daily Average: XXXXX  
X Week: XXXXX -XX%  
X Month: XXXXXX -XXXX%  
X Months: XXXXXXX -XX%  
X Year: XXXXXXXXX +82%  
1-Year High: XXXXXXX on 2025-01-02  
1-Year Low: X on 2025-10-11  

Engagements by network (24h):
Reddit: X
X: XXX

  
  
### Mentions: XX (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$nmra/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$nmra/time-series/posts_active.tsv)  
Current Value: XX  
Daily Average: XX  
X Week: XXX -XX%  
X Month: XXX +3.40%  
X Months: XXXXX +24%  
X Year: XXXXX +196%  
1-Year High: XXX on 2025-01-02  
1-Year Low: X on 2025-10-11  

Mentions by network (24h):
Reddit: X
X: XXX

  
  
### Creators: XX (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$nmra/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$nmra/time-series/contributors_active.tsv)  
XX unique social accounts have posts mentioning Neumora Therapeutics, Inc. Common Stock (NMRA) in the last XX hours which is down XX% from XXX in the previous XX hours
Daily Average: XX  
X Week: XXX -XXXX%  
X Month: XXX +6.50%  
X Months: XXXXX +90%  
X Year: XXXXX +143%  
1-Year High: XXX on 2025-01-06  
1-Year Low: X on 2025-10-11  

The most influential creators that mention Neumora Therapeutics, Inc. Common Stock in the last XX hours

| Creator                                              | Rank | Followers | Posts | Engagements |
| -------                                              | ---- | --------- | ----- | ----------- |
| [@StockTickerZone](/creator/twitter/StockTickerZone) | X    | XXXXX     | X     | XX          |
| [@indian20062](/creator/twitter/indian20062)         | X    | X         | X     | XX          |
| [@sarah_poun1015](/creator/twitter/sarah_poun1015)   | X    | XX        | X     | XX          |
| [@StockwiseTweet](/creator/twitter/StockwiseTweet)   | X    | XX        | X     | XX          |
| [@Top_Trader12](/creator/twitter/Top_Trader12)       | X    | XX        | X     | XX          |
| [@Dylanas19087](/creator/twitter/Dylanas19087)       | X    | X         | X     | X           |
| [@Stock_Analysi10](/creator/twitter/Stock_Analysi10) | X    | XX        | X     | X           |
| [@HollPabla39969](/creator/twitter/HollPabla39969)   | X    | XX        | X     | X           |

[View More](/list/creators/$nmra/100)
  
  
### Sentiment: X%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$nmra/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$nmra/time-series/sentiment.tsv)  
Current Value: X%  
Daily Average: XX%  
X Week: X% -XX%  
X Month: X% -XX%  
X Months: X% -XX%  
X Year: X% -XX%  
1-Year High: XXX% on 2025-04-06  
1-Year Low: X% on 2025-12-09  

Most Supportive Themes:
- R&D Day and Company Events: (5%) Announcements about Neumora Therapeutics' R&D Day and other company-related events generate positive attention.
- Potential Price Increases: (10%) Posts highlight potential for price increases due to momentum, with mentions of SMA crossovers and increased trading activity in related stocks.
  
Most Critical Themes:
- Stock Losses and Negative Sentiment: (50%) Numerous posts report losses and a declining stock price, fueled by negative analyst ratings and market downturn.
- Concerns about M4 Specificity: (25%) Some posts question the benefits of M4 specificity based on comparisons with other companies' clinical data.
  
  
  
### Social Dominance: XXXXXXX%
![Social Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:$nmra/c:line/m:social_dominance/iv:1d.svg)  
[Social Dominance 24-Hour Time-Series Raw Data](/topic/$nmra/time-series/social_dominance.tsv)  
Current Value: XXXXXXX%  
Daily Average: XXXXX%  
X Week: XXXXXX% +0.0039%  
X Month: XXXXX% -XXXXXX%  
X Months: XXXXX% +0.013%  
X Year: XXXXX% +0.0013%  
1-Year High: XXXXX% on 2025-01-02  
1-Year Low: XXXXXX% on 2025-10-11  
  
  
### Market Dominance: XXXXXXXXXXXXXXXXXXXXX%
![Market Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:$nmra/c:line/m:market_dominance/iv:1d.svg)  
[Market Dominance 24-Hour Time-Series Raw Data](/topic/$nmra/time-series/market_dominance.tsv)  
Current Value: XXXXXXXXXXXXXXXXXXXXX%  
Daily Average: X%  
1-Year High: XXXXXXX% on 2025-03-31  
1-Year Low: XXXXXXX% on 2025-05-14  
  
  
### Market Cap: $XXXXXXXXXXX
![Market Cap Line Chart](https://lunarcrush.com/gi/w:600/t:$nmra/c:line/m:market_cap/iv:1d.svg)  
[Market Cap 24-Hour Time-Series Raw Data](/topic/$nmra/time-series/market_cap.tsv)  
Current Value: $XXXXXXXXXXX  
Daily Average: $XXXXXXXXXXX  
X Week: $XXXXXXXXXXX -$11%  
X Month: $XXXXXXXXXXX -$17%  
X Months: $XXXXXXXXXXX +$143%  
X Year: $XXXXXXXXXXX -$79%  
1-Year High: $XXXXXXXXXXXXX on 2024-12-26  
1-Year Low: $XXXXXXXXXX on 2025-05-14  

### Top Neumora Therapeutics, Inc. Common Stock Social Posts
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"$NMRA $NOK Guys Don't miss the next move in a few hours. =-"  
[X Link](https://x.com/Evie71425/status/1998436232523907272) [@Evie71425](/creator/x/Evie71425) 2025-12-09T16:55Z XX followers, XX engagements


"The R&D pipeline for depression therapies faced a demoralizing 2025 as five high-profile candidates including KOR antagonists by Johnson & Johnson and Neumora Therapeutics flunked late-stage clinical trials underscoring the persistent challenges of CNS drug development"  
[X Link](https://x.com/biospace/status/1998136498491687150) [@biospace](/creator/x/biospace) 2025-12-08T21:03Z 25.4K followers, XXX engagements


"$NMRA Guys Don't miss the Target price for Next Week 🔜"  
[X Link](https://x.com/StockwiseTweet/status/1998083517109219382) [@StockwiseTweet](/creator/x/StockwiseTweet) 2025-12-08T17:33Z XX followers, XX engagements


"$NMRA Guys Don't miss the next move in a few hours 💸➡"  
[X Link](https://x.com/OwenLay81/status/1997855263395832185) [@OwenLay81](/creator/x/OwenLay81) 2025-12-08T02:26Z XX followers, XX engagements